What is Ablacon?
Founded in 2015 and headquartered in Wheat Ridge, Colorado, Ablacon is at the forefront of developing innovative electrotherapy solutions for Atrial Fibrillation (AFib) and other heart rhythm disorders. The company leverages a proprietary artificial intelligence algorithm to meticulously analyze and visualize the Electrographic Flow within the heart, enabling precise identification of AFib sources. This technological approach positions Ablacon as a key player in the medtech sector, aiming to improve patient outcomes through advanced diagnostics and therapeutic interventions.
How much funding has Ablacon raised?
Ablacon has raised a total of $63.5M across 4 funding rounds:
Multiple Rounds
$33.5M
Series B
$30M
Series A (2019): $21.5M with participation from Ajax Health
Debt (2019): $10M led by Western Technology Investment
Private Equity (2019): $2M supported by Western Technology Investment
Series B (2021): $30M featuring Zeus Health Products Ltd
Key Investors in Ablacon
Zeus Health Products Ltd
Zeus Health Products Ltd is an investor in Ablacon's Series B funding round. Further details on their investment focus are not publicly available.
Western Technology Investment
Western Technology Investment (WTI) specializes in providing venture debt to assist startups in financing their growth while minimizing shareholder dilution. Since its inception in 1980, WTI has supported over 1,400 companies across various innovation sectors, demonstrating a long history of capital provision through diverse economic cycles.
Ajax Health
Ajax Health is a venture capital firm that has provided Series A funding to Ablacon. Their investment indicates a focus on early-stage healthcare companies with disruptive potential.
What's next for Ablacon?
With its recent major strategic investment and substantial overall capital, Ablacon is poised for significant expansion. The company's focus on AI-driven analysis of cardiac electrograms suggests a trajectory towards refining its electrotherapy solutions and potentially broadening its application to other complex cardiac conditions. This funding round, likely a Series B given the enterprise-level context, indicates a transition from development to scaling operations, including further clinical validation, market outreach, and potential commercialization efforts. Ablacon's strategic financing will be critical in navigating the competitive landscape of cardiovascular medical devices.
See full Ablacon company page
